About Integrin alpha-7
Integrin alpha-7 (ITGA7) is a protein
from Homo sapiens identified by UniProt accession
Q13683, 1181 residues long.
MolForge cross-references it against 0 known binders and
323 disease associations.
Target properties
| Protein name | Integrin alpha-7 |
|---|
| UniProt accession | Q13683 |
|---|
| Gene | ITGA7 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1181 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (323)
Diseases linked to this target (Open Targets).
- Congenital muscular dystrophy with integrin alpha-7 deficiency · score 0.75
- congenital muscular dystrophy due to integrin alpha-7 deficiency · score 0.73
- neurodegenerative disease · score 0.53
- congenital muscular dystrophy · score 0.46
- congenital fiber-type disproportion myopathy · score 0.37
- Abnormal brain morphology · score 0.27
- breast adenocarcinoma · score 0.25
- lung adenocarcinoma · score 0.18
- head and neck squamous cell carcinoma · score 0.12
- gastric adenocarcinoma · score 0.10
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q13683-F1 | alphafold | PREDICTED | 79.18 | — |
Amino-acid sequence (1181 residues)
MAGARSRDPW GASGICYLFG SLLVELLFSR AVAFNLDVMG ALRKEGEPGS LFGFSVALHR QLQPRPQSWL LVGAPQALAL PGQQANRTGG LFACPLSLEE TDCYRVDIDQ GADMQKESKE NQWLGVSVRS QGPGGKIVTC AHRYEARQRV DQILETRDMI GRCFVLSQDL AIRDELDGGE WKFCEGRPQG HEQFGFCQQG TAAAFSPDSH YLLFGAPGTY NWKGTARVEL CAQGSADLAH LDDGPYEAGG EKEQDPRLIP VPANSYFGLL FVTNIDSSDP DQLVYKTLDP ADRLPGPAGD LALNSYLGFS IDSGKGLVRA EELSFVAGAP RANHKGAVVI LRKDSASRLV PEVMLSGERL TSGFGYSLAV ADLNSDGWPD LIVGAPYFFE RQEELGGAVY VYLNQGGHWA GISPLRLCGS PDSMFGISLA VLGDLNQDGF PDIAVGAPFD GDGKVFIYHG SSLGVVAKPS QVLEGEAVGI KSFGYSLSGS LDMDGNQYPD LLVGSLADTA VLFRARPILH VSHEVSIAPR SIDLEQPNCA GGHSVCVDLR VCFSYIAVPS SYSPTVALDY VLDADTDRRL RGQVPRVTFL SRNLEEPKHQ ASGTVWLKHQ HDRVCGDAMF QLQENVKDKL RAIVVTLSYS LQTPRLRRQA PGQGLPPVAP ILNAHQPSTQ RAEIHFLKQG CGEDKICQSN LQLVRARFCT RVSDTEFQPL PMDVDGTTAL FALSGQPVIG LELMVTNLPS DPAQPQADGD DAHEAQLLVM LPDSLHYSGV RALDPAEKPL CLSNENASHV ECELGNPMKR GAQVTFYLIL STSGISIETT ELEVELLLAT ISEQELHPVS ARARVFIELP LSIAGMAIPQ QLFFSGVVRG ERAMQSERDV GSKVKYEVTV SNQGQSLRTL GSAFLNIMWP HEIANGKWLL YPMQVELEGG QGPGQKGLCS PRPNILHLDV DSRDRRRREL EPPEQQEPGE RQEPSMSWWP VSSAEKKKNI TLDCARGTAN CVVFSCPLYS FDRAAVLHVW GRLWNSTFLE EYSAVKSLEV IVRANITVKS SIKNLMLRDA STVIPVMVYL DPMAVVAEGV PWWVILLAVL AGLLVLALLV LLLWKMGFFK RAKHPEATVP QYHAVKIPRE DRQQFKEEKT GTILRNNWGS PRREGPDAHP ILAADGHPEL GPDGHPGPGT A
Explore Integrin alpha-7 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets